TabletsClinical Overview
Empagliflozin (10 mg, 25 mg) is a highly selective SGLT2 inhibitor on the WHO Model List of Essential Medicines with landmark proven cardiovascular and renal mortality benefits. It selectively inhibits SGLT2 in the renal proximal convoluted tubules, promoting glycosuria and natriuresis, improving systemic hemodynamics, and reducing cardiac ventricular wall stress. Indicated for type 2 diabetes mellitus, reduction of cardiovascular death in adults with T2D and established CVD, heart failure (across the entire spectrum of LVEF), and chronic kidney disease.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily in the morning with water, with or without food. Drink plenty of water throughout the day.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Genital mycotic infections, urinary frequency, dysuria, volume depletion, thirst. Rare/Severe: Euglycemic diabetic ketoacidosis (DKA), Fournier's gangrene, pyelonephritis, and severe hypotension.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Hold at least 3 days prior to scheduled major surgery. Educate patients on euglycemic DKA symptoms. Ensure adequate daily fluid intake to prevent postural hypotension.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Empagliflozin Tablets 10 mg
Empagliflozin (10 mg, 25 mg) is a highly selective SGLT2 inhibitor on the WHO Model List of Essential Medicines with landmark proven cardiovascular and renal mortality benefits. It selectively inhibits SGLT2 in the renal proximal convoluted tubules, promoting glycosuria and natriuresis, improving systemic hemodynamics, and reducing cardiac ventricular wall stress. Indicated for type 2 diabetes mellitus, reduction of cardiovascular death in adults with T2D and established CVD, heart failure (across the entire spectrum of LVEF), and chronic kidney disease.
Empagliflozin 10mg + Linagliptin 5mg Tablets
Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.
Empagliflozin 25mg + Linagliptin 5mg Tablets
Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.